You are here

SPIRIT 2

STI571 Prospective International RandomIsed Trial 2: A phase III, prospective randomised comparison of imatinib (STI571, Glivec/Gleevec) 400mg daily versus dasatinib (Sprycel) 100mg daily in patients with newly-diagnosed chronic phase chronic myeloid leukaemia.
Recruitment period: 
1 January 2012 to 3 August 2013
Trial period: 
1 January 2012 to 3 August 2013

Treatments:

For newly diagnosed patients: 
no

This clinical trial is closed

UK Multi-Centre
Lead Country: England (also active in Scotland and Northern Ireland and Wales)

Current Status: Closed – in follow-up
Closure Date: 3 August 2013
Global Sample Size: 810
Global Recruitment to Date: 100%

Research Summary

SPIRIT2 is a Phase III, multicentre, open-label, prospective randomised trial comparing imatinib 400 mg daily versus dasatinib 100 mg daily in patients with newly-diagnosed chronic phase Chronic Myeloid Leukaemia (CML).

http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=5266